A healthy bone marrow responds to the body’s chemical signals that essentially communicate the need to boost blood cell production. Most of the hematopoietic stem cells live and work in the bone marrow. Hematopoietic stem cells give rise to all types of blood cells such as White Blood Cells, Red Blood Cells, and platelets.
Without a healthy bone marrow, blood cell production suffers and new ones cannot be made. One of the side effects of chemotherapy in cancer patients is damage to the bone marrow, which hinders the ability to develop new blood cells, especially WBC. Hematologic malignancies are also responsible for an unhealthy bone marrow. Pharmaceutical companies have developed drugs known as growth factors or colony-stimulating factors that can be used to boost the production of blood cells.
There is a rise in the use of therapies such as chemotherapy and radiotherapy, which lead to damage to the bone marrow. This is boosting demand for bone marrow stimulator drugs in the market. According to the World Cancer Research Fund International, there were an estimated 18 million cancer cases around the world in 2018. Moreover, the Global Burden of Disease study data stated that the incidence of leukemia increased by 26% from 2006 to 2016.
Request a Discount of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=61641
The global bone marrow stimulator drugs market can be segmented based on drugs class, distribution channel, and region. Based on drug class, the global bone marrow stimulator drugs market can be classified into filgrastim, lenograstim, and others. The filgrastim segment dominated the bone marrow stimulator drugs market in 2017. This is because filgrastim is a non-glycosylated stimulating factor that effectively binds with the bone marrow and stimulates it to develop WBCs in large numbers. In terms of distribution channel, the bone marrow stimulator drugs market can be categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment dominates the market. This is because bone marrow stimulator drugs can be given to patients under observation in order to check the effect of the drugs on WBC count. Therefore, a large number of patients prefer to buy the drugs through hospital pharmacies.
In terms of region, the global bone marrow stimulator drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017. The region is projected to account for a significant share of the global bone marrow stimulator drugs market during the forecast period, owing to a high incidence of cancer and wide availability of all the types of bone marrow stimulator drugs in North America. In 2018, Pfizer launched the bio similar drug of filgrastim called NIVESTYM in the U.S. market. High awareness about the effect of cancer treatment and rise in the incidence of blood disorders among the European population are expected to drive the bone marrow stimulator drugs market in Europe.
Request Customization @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=61641
Major players operating in the global bone marrow stimulator drugs market include Amgen Inc. Teva Pharmaceutical, Novartis AG, Pfizer Inc. F. Hoffmann-La Roche AG, and Lupin Pharmaceuticals, Inc..